Novartis to Acquire Avidity Biosciences for $12 Billion in Cash
TL;DR Summary
Novartis is acquiring U.S. biotech firm Avidity Biosciences for about $12 billion in cash, aiming to expand its RNA therapeutics portfolio and boost growth, with the deal expected to close in the first half of 2026 after Avidity spins out some of its business units.
- Novartis to buy U.S. biotech firm Avidity Biosciences for about $12 billion in cash CNBC
- Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline Novartis
- Novartis Said to Near at Least $70-Per-Share Deal for Avidity Bloomberg.com
- Novartis nears deal to acquire Avidity Biosciences for over $70 per share, Bloomberg News reports Reuters
- Novartis to buy RNA drugmaker Avidity Biosciences for $12B Endpoints News
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
86%
325 → 45 words
Want the full story? Read the original article
Read on CNBC